1. CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL

   Bouwstra, R., He, Y., de Boer, J. W., Kooistra, H., Cendrowicz, E., Fehrmann, R. S. N., Ammatuna, E., Eulenburg, C., Nijland, M., Huls, G., Bremer, E. & van Meerten, T., Oct-2019, In : Cancer immunology research. 7, 10, p. 1663-1671 9 p.

   Research output: Contribution to journal › Article › Academic › peer-review

2. Does cancer cell-expressed SLAMF7 impact on CD47-mediated phagocytosis?

   Bouwstra, R., van Meerten, T. & Bremer, E., 1-Jan-2019, In : Molecular and Cellular Oncology. 6, 3, 3 p., 1600349.

   Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

3. CD47 Expression Defines the Efficacy of Rituximab in Non-Germinal Center B-Cell (non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

   Van Meerten, T., Bouwstra, R., He, Y., Janneke, D. B., Kooistra, H., Fehrmann, R., Ammatuna, E., Huls, G. & Bremer, E., 29-Nov-2018, In : Blood. 132, Suppl.1, 3 p.

   Research output: Contribution to journal › Meeting Abstract › Academic

4. Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis

   He, Y., Bouwstra, R., Wiersma, V. R., de Jong, M., Lourens, H. J., Fehrmann, R., de Bruyn, M., Ammatuna, E., Huls, G., van Meerten, T. & Bremer, E., 1-Feb-2019, In : Nature Communications. 10, 1, 8 p., 533.

   Research output: Contribution to journal › Article › Academic › peer-review

View all (4) »